

1 Endocrine disrupting chemicals and COVID-19 relationships: a computational systems
2 biology approach

3

4 Qier Wu¹, Xavier Coumoul¹, Philippe Grandjean^{2,3}, Robert Barouki¹, Karine Audouze^{1*}

5

6 **Affiliations :**

7 ¹ Université de Paris, T3S, Inserm UMR S-1124, F-75006 Paris, France

8 ² Harvard T.H.Chan School of Public Health, Boston, MA 02215, USA

9 ³ University of Southern Denmark, 5000 Odense C, Denmark

10 * Corresponding author: karine.audouze@u-paris.fr_tel: + 33 142 864 010, Université de
11 Paris, T3S, Inserm UMR-S 1124, 45 rue des Saints-Pères- F-75006 Paris, France

12

13 **Abstract**

14 Background: Patients at high risk of severe forms of COVID-19 frequently suffer from chronic
15 diseases, but other risk factors may also play a role. Environmental stressors, such as
16 endocrine disrupting chemicals (EDCs), can contribute to certain chronic diseases and might
17 aggravate the course of COVID-19.

18 Objectives: To explore putative links between EDCs and COVID-19 severity, an integrative
19 systems biology approach was constructed and applied.

20 Methods: As a first step, relevant data sets were compiled from major data sources.

21 Biological associations of major EDCs to proteins were extracted from the CompTox
22 database. Associations between proteins and diseases known as important COVID-19
23 comorbidities were obtained from the GeneCards and DisGeNET databases. Based on these
24 data, we developed a tripartite network (EDCs-proteins-diseases) and used it to identify
25 proteins overlapping between the EDCs and the diseases. Signaling pathways for common
26 proteins were then investigated by over-representation analysis.

27 Results: We found several statistically significant pathways that may be dysregulated by
28 EDCs and that may also be involved in COVID-19 severity. The Th17 and the AGE/RAGE
29 signaling pathways were particularly promising.

30

31

32 Conclusions: Pathways were identified as possible targets of EDCs and as contributors to
33 COVID-19 severity, thereby highlighting possible links between exposure to environmental
34 chemicals and disease development. This study also documents the application of
35 computational systems biology methods as a relevant approach to increase the
36 understanding of molecular mechanisms linking EDCs and human diseases, thereby
37 contributing to toxicology prediction.

38

39 **Keywords:** endocrine disruptor, systems toxicology, integrative computational approach,
40 network science, OBERON

41 Introduction

42 The COVID-19 pandemic started in the fall of 2019 and spread to a large part of the
43 world during the winter and spring of 2020. By late June 2020, it had led to more than
44 500,000 deaths, of which one-fourth in the US and about 175,000 in the EU
45 (<https://coronavirus.jhu.edu/map.html>, <https://covid19.who.int/>). Despite considerable
46 research activities, there are still many unknowns concerning this infectious disease,
47 especially with regard to the substantial variability of the disease severity. Following an
48 initial infectious phase, a “cytokine storm”, leading to pneumonia is observed in severe cases
49 which may require intensive care. It is still unclear why infections lead to severe cases in
50 some patients and not in others, but both endogenous and exogenous factors can likely
51 influence the outcome of the disease.

52 In addition to older age and male sex, several comorbidities are associated with
53 severe COVID-19 and increased mortality risk. Disorders such as cardiovascular disease, type
54 II diabetes (T2D), obesity, chronic respiratory disease or hypertension are strongly linked to
55 severe COVID-19 cases (Petrilli et al. 2020)(Zhou et al. 2020)(Stefan et al. 2020). As has
56 recently been proposed, underlying metabolic and endocrine dysfunctions may be
57 mechanistically linked to the exacerbation of the coronavirus infection (Bornstein et al.
58 2020), and these observations may inspire new insight into the pathogenesis of this disease,
59 including biological interpretation of the mechanisms involved. Environmental stressors
60 have already been suggested to contribute to the severity of the disease (Bashir et al. 2020;
61 Fattorini and Regoli 2020; Zhu et al. 2020), but little mechanistic support for this association
62 is available. A relevant approach would be to compare the biological pathways triggered by
63 environmental stressors with those involved in the COVID-19 severity. If similar pathways
64 are found, this would increase the likelihood that such stressors may contribute to critical
65 stages of this disease.

66 Given the suspected hormonal mode of vulnerability (Drucker 2020) endocrine
67 disrupting chemicals (EDCs) could represent important triggers of aggravated infection, e.g.,
68 in the form of phthalates, bisphenols, organochlorine pesticides, and perfluorinated alkane
69 substances (PFASs) (Trasande et al. 2016; Vandenberg et al. 2016). Exposure to these
70 substances may affect the immune defense, thus potentially increasing the susceptibility to
71 develop COVID-19 (Tsatsakis et al. 2020), as supported by experimental studies(Cipelli et al.
72 2014; Couleau et al. 2015). For example, epidemiological evidence on children exposed to

73 PFASs show decreased immune responses to routine vaccines (Grandjean et al. 2012) and a
74 greater risk of developing infectious disease(Dalsager et al. 2016; Granum et al. 2013).

75 As promising tools to gain better insight into the possible risk factors and
76 mechanisms, toxicological and chemical data sources have expanded substantially, thereby
77 enabling network science and computational systems biology methods to become feasible
78 (Audouze et al. 2013, 2018; Taboureau and Audouze 2017; Vermeulen et al. 2020; Wu et al.
79 2020). We have therefore conducted an integrative systems biology exploration to identify
80 overlapping proteins that are both dysregulated by EDCs and involved in comorbidities
81 associated with aggravated COVID-19. Based on this tripartite network, integrating protein-
82 EDC associations and protein-disease annotations, we then performed biological
83 enrichments of pathways to detect the most plausible relationships between EDC exposure
84 and COVID-19 severity.

85

86

87 **Methods**

88 We employed a computational systems biology approach to explore putative linkages
89 between EDCs and COVID-19 as presented in Figure 1. First, a tripartite network was created
90 based on known associations between proteins and either COVID-19 comorbidities or EDCs,
91 as compiled from existing databases (CompTox, DisGeNET, GeneCards) (A). Then, biological
92 enrichment was performed with the jointly identified proteins (i.e., those retrieved in both
93 association studies) (B) by over-representation analysis (ORA) to identify the pathways that
94 were the highly linked to both the diseases and the EDCs (C). As a final step, the biological
95 pathways were explored with available knowledge regarding COVID-19 mechanisms (from
96 the literature and the AOP-Wiki database), thereby allowing consideration of hypothetical
97 linkages between EDCs and COVID-19 (D).

98 ***Endocrine-disrupting chemical dataset***

99 A list of 34 commonly used substances known or suspected to act as EDCs was established,
100 based on knowledge from three data sources: the endocrine disruptor assessment list from
101 ECHA (<https://echa.europa.eu/fr/ed-assessment>, as of April 24, 2020), the one from NIEHS
102 (<https://www.niehs.nih.gov/health/topics/agents/endocrine/index.cfm> as of April 28, 2020),
103 and the TEDX database ([https://endocrinedisruption.org/interactive-tools/tedx-list-of-](https://endocrinedisruption.org/interactive-tools/tedx-list-of-potential-endocrine-disruptors/search-the-tedx-list)
104 [potential-endocrine-disruptors/search-the-tedx-list](https://endocrinedisruption.org/interactive-tools/tedx-list-of-potential-endocrine-disruptors/search-the-tedx-list), as of April 24, 2020).

105 To explore as much as possible the chemical diversities, EDCs for this study were further
106 selected to represent different chemical classes (Table 1). The CAS numbers were used for
107 data integration.

108 ***Disease dataset***

109 Comorbidities known to be associated with obesity or otherwise leading to severe COVID-19
110 were extracted from a recent study (Stefan et al. 2020), and resulted in a total of 13
111 disorders for exploration in the integrative systems toxicology (Table2).

112 ***Endocrine-disrupting chemical-protein associations***

113 Human proteins known to be associated with each of the 34 EDCs were extracted from the
114 U.S. Environmental Protection Agency web-based CompTox Chemistry dashboard, which
115 contains a wide range of data related to chemical toxicity, including *in vitro* bioassays data
116 (as of April 30, 2020) (Williams et al. 2017). Each linked protein was matched to a gene
117 symbol and classified using the Panther (protein analysis through evolutionary relationships)
118 classification system (version 15, released February 14, 2020) (Mi et al. 2013), a curated

119 biological database of gene/protein families, and their functionally related subfamilies that
120 can be used to classify and identify the function of gene products.

121 ***Disease-protein associations***

122 From two human protein-disease databases, proteins known to be linked to the 13 studied
123 diseases were listed (as of April 29, 2020 for both data sources). The DisGenNet database is a
124 discovery platform containing one of the largest publicly available collections of genes and
125 variants associated with human diseases (Piñero et al. 2015). The GeneCards database
126 contains manually curated information for substances and their associations to genes and
127 proteins, that are scored (Safran et al. 2010). For the present study, only associations were
128 kept only for those between human diseases and proteins categorized as coding proteins,
129 and all non-human information, including gene clusters, genetic locus, pseudogenes, RNA
130 genes and those uncategorized were disregarded. All listed proteins were matched to their
131 gene symbol to facilitate further analysis. Each identified protein from both databases, was
132 categorized into the protein class using the Panther classification (version 15).

133 ***Pathways enrichment analysis***

134 To decipher biological pathways potentially linked to the selected EDCs and explore if they
135 might overlap with the ones known for COVID-19, an ORA was done. Four major sources of
136 protein-pathway information were independently integrated, i.e., using the Kyoto
137 Encyclopedia of Genes and Genomes (KEGG), the Reactome, the Wiki-pathways and the
138 Panther databases (Fabregat et al. 2018; Kanehisa et al. 2019; Mi et al. 2013; Slenter et al.
139 2018). To assess the statistical significance of the protein-pathway relationships, a
140 hypergeometric test was used for each of the four sources, followed by a multiple testing
141 correction of the p -values with the Benjamini-Hochberg method. The ORA was performed on
142 the common proteins identified to identify the most strongly linked proteins that are
143 affected by the EDCs and also associated with at least one the 13 comorbidities. As a last
144 step, manual curation allowed us to consider relevant outcomes for interpretation. The four
145 data sources provided complementary information, with some overlapping findings.

146 ***COVID-19 and biological mechanism of action***

147 Linkage between COVID-19 and potential biological targets and affected pathways were
148 extracted from the literature (as of May 22, 2020) and the AOP-Wiki database (as of May 22,
149 2020).

150

151 **Results**

152 ***Endocrine-disrupting chemical-protein associations***

153 From the CompTox database, information on the links between chemicals and human
154 proteins were compiled. Data for 30 of the 34 chemicals could be retrieved, and a total of
155 208 unique human proteins were involved via 1632 associations. No information was
156 retrieved for hexachlorobenzene, nonylphenol ethoxylate, perchlorate and tributyltin.
157 Perfluorooctane sulfonic acid (PFOS) targeted the highest number of proteins (113), and
158 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) was associated with only one biological target
159 (the progesterone receptor). The most frequently affected proteins included the androgen
160 receptor (AR) and the estrogen receptor-alpha (ESR1), which were each linked to 23 EDCs,
161 whereas 61 individual proteins were associated with only one EDC.

162 To identify the biological targets that are most often affected by EDCs, proteins were
163 grouped in clusters according to their families, as based on the Panther classification system
164 (Figure 2). The majority of the 208 proteins related to EDCs belonged to 12 classes among
165 the 23 present in Panther, while the remaining proteins were classified as 'uncategorized
166 protein class'. Each protein was assigned to only one category, although only one of them,
167 HLA-DRA, (HLA class II histocompatibility antigen, DR alpha chain) belonged to the
168 defense/immunity group. Other immunity-related proteins, such as interleukin 6 (IL-6) or
169 interleukin 1 alpha (IL-1A), were not associated with any class in the Panther classification.
170 We therefore manually added all immune system-related proteins to the "uncategorized
171 class". Given that Bisphenol A (BPA) increases the release of these proteins (Ben-Jonathan et
172 al. 2009), and because antibodies to the IL-6 receptor (such as tocilizumab) or to the IL-1
173 receptor (such as Anakinra) are currently tested for the treatment of COVID-19 patients
174 (Zhou et al. 2020), we also explored if the proteins selected could be mapped to defense
175 and/or immunity biological categories. For this purpose, we used the Gene Ontology (GO)
176 classification (as of May 26, 2020), and among the 208 proteins dysregulated by EDCs, 58
177 were associated with inflammatory response, 75 with defense response, and 66 with
178 regulation of immune system process.

179 ***Disease-protein associations***

180 Regarding diseases associated with human proteins, two databases were screened. From the
181 DisGeNET database, we were able to retrieve information for 8 of the 13 diseases, which
182 were connected to 3262 unique proteins via 7195 links (as of April 29, 2020). The proteins

183 were categorized in 22 protein classes using the Panther classification (version 15) (Figure
184 S1). Proteins that did not belong in any class were again grouped into the uncategorized
185 class. Obesity and diabetes were linked to proteins belonging to each of the 22 categories,
186 whereas insulin resistance and dyslipidemia were linked to only half of the categories.
187 From the GeneCards database, all 13 predisposing diseases were retrieved (as of 29 April
188 2020), and a total of 115,289 associations were identified between the diseases and 29,094
189 unique human proteins were extracted. Among them, only protein-coding information
190 according to HGNC, Ensembl or Entrez Gene were kept (proteins data related to biological
191 regions, gene clusters, genetic loci, pseudogenes, non-coding RNA genes and uncategorized
192 elements were not considered), thereby reducing the total number of unique protein to
193 18,931, representing 97,855 disease-protein links. As a next step, grouping of the proteins
194 using the Panther classification system allowed identification of 23 clusters correspond to
195 the 23 different protein classes (Figure S2). Each protein was assigned to only one category,
196 except for ameloblastin (AMBN), which was associated with both 'extracellular matrix
197 protein' and 'structural protein'. Proteins not associated with Panther classes, were again
198 grouped into the uncategorized class. Excluding the viral or transposable element protein
199 class, all diseases (except dyslipidemia) were associated with all the other Panther classes.
200 In order to keep the most relevant protein-disease associations obtained from the
201 GeneCards database, data were filtered based on their scores. The GeneCards scores are
202 calculated based on publications mentioning a protein and a disease, using a Boolean model.
203 The higher the score, the more relevant the protein-disease association is. Among the
204 97,855 links between the 13 diseases and 18,931 proteins, the score values ranged between
205 0.13 (representing very low association) to 228 (very high evidence for a protein-disease
206 connection). After evaluation of the extracted data (number of proteins by GeneCards
207 scores), we selected associations with a score ≥ 20 (see Figure S3). Within this threshold, a
208 total of 5732 associations were retained that link the 12 diseases with 2079 unique human
209 proteins (no information was retained for 'dyslipidemias' from the GeneCards database).

210 ***Generating a tripartite network of protein-EDC-disease associations***

211 A human bipartite associative network of proteins and the 13 diseases was created. Among
212 the 3262 unique proteins from the DisGeNET, and the 2079 proteins from the GeneCards
213 databases, 1157 were overlapping proteins and only 922 and 2105 proteins were uniquely
214 associated with GeneCards or DisGeNET, respectively. All 4184 unique proteins were again

215 grouped into 23 clusters using the Panther classification (the class ‘viral or transposable
216 element protein’ was not kept after the cleaning step. Among the groupings, we retrieved a
217 cluster of proteins linked to the ‘defense/immunity’ category. These results were merged
218 with the bipartite protein-EDCs network to develop a tripartite network (Figure 2).

219 ***Translation into pathways***

220 To identify biological pathways that may be involved in the predisposing diseases while also
221 being dysregulated by the EDCs, we first analyzed the overlaps between the two sets of
222 proteins. Among the proteins identified from the three data sources, 98 were common
223 (Figure S4), and all of them were mapped to unique Entrez GeneID, and could therefore be
224 used for biological enrichment analyses, which were performed independently using four
225 data sources (KEGG, Reactome, Wiki-pathways and Panther). The ORA analysis revealed
226 several statistically significant pathways linked to interleukins/cytokines signaling,
227 intracellular signaling pathways and, regulation of metabolic pathways (Table 3).
228 Interestingly, the different data sources showed very significant associations with common
229 pathways, such as interleukins (IL) related pathways: IL-4 and IL-13, IL-10 signaling pathways
230 ($p_{\text{adj}} < E-16$, and p_{adj} of $2.85E-09$ respectively, Reactome), IL-17 signaling pathway (p_{adj} of
231 $1.05E-10$, KEGG), IL-3, IL-5 and IL-18 signaling pathways (p_{adj} of $1.09E-09$, $2.52E-09$, $1.49E-08$
232 respectively, Wiki-pathways), the IL-signaling pathways (p_{adj} of $1.10E-05$, Panther); or the
233 Toll-like receptor signaling pathway (p_{adj} $3.91E-09$ for KEGG, p_{adj} of 0.99 for Panther and p_{adj}
234 $1.93E-08$ for Wiki-pathways).

235 Among the most significant pathways, several were retrieved from each of the data sources
236 with relation to the AGE/RAGE pathway (*i.e.* Advanced Glycation End products and its
237 receptor), which is known to cause cellular stress and inflammation. The AGE are formed
238 non-enzymatically, by Maillard reaction products (carbohydrates with proteins and/or lipids)
239 and bind to the RAGE. Formation of AGE has been associated with chronic diseases such as
240 type 2 diabetes (Cai et al. 2012; Menini et al. 2018). Similarly, the stress or inflammatory
241 pathways (e.g shear stress, defined as the tangential force exerted by the blood flow on the
242 vascular endothelium, TNF-alpha) are highlighted by our analysis; the shear stress activates
243 the AhR signaling pathway, which is also involved in the regulation of IL-17 production by the
244 Th17 lymphocytes; interleukin 17 has been suspected to be involved in the pathogenesis of
245 COVID19 (Gutiérrez-Vázquez and Quintana 2018; Han et al. 2008; Pacha et al. 2020).
246 Interestingly, inflammation is suspected to influence insulin resistance.

247 ***Exploration of EDCs linkage to COVID-19***

248 To explore putative links between COVID-19 and exposure to EDCs, we first screened the
249 AOP-Wiki database, and then further examined the pathways identified using literature
250 references.

251 In the AOP-Wiki database, only one AOP was related to COVID-19, and it involves several key
252 events, such as 'increased pro-inflammatory mediators' (KE 1496), 'increased inflammatory
253 immune responses' (KE 1750), which leads to the adverse outcome 'increased mortality' (AO
254 351). Such knowledge-based linear chain of events highlights the importance of the link
255 between COVID-19 and inflammatory processes.

256

257

258 **Discussion**

259 In order to investigate possible links between exposure to EDCs and the severity of COVID-
260 19, we explored a computational systems biology approach. The tripartite network model
261 first linked EDCs to targeted proteins and then proteins related to diseases that predispose
262 to more serious COVID-19 development, thereby allowing us to identify common signaling
263 pathways. The identification of such joint pathways and their role as possible targets of EDCs
264 highlights the potential links between exposure to environmental chemicals and COVID-19
265 severity.

266 This integrative approach can be easily applied as a new approach methodology (NAM)
267 (Bopp et al. 2019), which may offer support to methods alternative to animal testing or to
268 identify biological pathways that require more focused laboratory study. Previous studies
269 have demonstrated that systems chemical toxicology models combined with computational
270 network biology may help in understanding chemical toxicity in humans (Hartung et al. 2017;
271 Nie et al. 2015; Taboureau and Audouze 2017). Our tripartite network supports the notion
272 that exposure to EDCs may contribute to aggravation of COVID-19. Although major links
273 were identified at extremely low p values, the approach relies on existing information
274 available in within the very substantive data sources, but some causal associations may have
275 been overlooked or disregarded because of missing or incomplete information.

276 To assess the validity of our approach, a more focused expert analysis was attempted, where
277 we selected the Th17 and the AGE/RAGE signaling pathways because of their
278 pathophysiological relevance in the context of COVID-19. The interleukin-17 (IL-17) signaling
279 pathway plays several important roles, and IL-17 is produced by a pro-inflammatory subtype
280 of T helper lymphocytes named Th17 cells, located at mucosal barriers where they
281 contribute to pathogen clearance. The IL-17 produced stimulates the synthesis of cytokines
282 (IL1 β , TNF-alpha...) and chemokines (MCP-1...) by other cell types, thereby favoring the
283 recruitment of monocytes and neutrophils at inflammatory sites. However, an over-
284 activation of Th17 cells can lead to a hyper-inflammatory state which is deleterious (Pacha et
285 al. 2020).

286 The highly variable symptomatology associated with the infection by SARS-CoV-2 depends
287 on the levels of IL-17 and of other cytokines including IL-1 β , IL-6, IL-15, TNF-alpha and IFN γ .
288 The most deleterious effect of SARS-CoV-2 in humans is an acute lung injury leading to a
289 severe acute respiratory syndrome (SARS) that is partly due to IL-17-related excessive

290 recruitment of pro-inflammatory cells and production of pro-inflammatory cytokines.
291 Therefore, an increased basal level of IL-17 (in the absence of infection, for example due to
292 obesity or to induction by a chemical) might represent a lung injury risk associated with
293 SARS-CoV-2 infection. Our finding of EDC linkage to this pathway is therefore of high
294 pathogenetic relevance.

295 Obesity promotes a high basal level of inflammation which contributes to insulin resistance
296 and type 2 diabetes(Goldberg 2009). This phenomenon is due to an infiltration of the
297 adipose tissue (AT) by macrophages and T cells and their production of various pro-
298 inflammatory cytokines, including IL-1 β , TNF-alpha, IL-17 and IL-6. Several EDCs are
299 suspected to be obesogenic (and are subsequently named obesogens). This has been
300 demonstrated for several substances (e.g. tributyltin) and linked to the stimulation of pro-
301 adipogenic signaling pathway (e.g. through PPAR γ)(Egusquiza and Blumberg 2020). Similarly,
302 the aryl hydrocarbon receptor (AhR) is highly expressed in Th17 cells and is an essential
303 contributor to the production of IL-17(Veldhoen et al. 2008). The AhR, known as the
304 receptor of dioxins and dioxin-like PCBs, is also activated by shear stress (SS), another
305 pathway highlighted in our computational analysis. Indeed, several studies have shown using
306 various endothelial models that laminar SS leads to the activation of two target genes of the
307 AhR, namely CYP1A1 and CYP1B1(Conway et al. 2009). Two recent studies suggest an
308 indirect link between SARS-CoV-2 and SS by showing that the expression of ACE2
309 (angiotensin-converting enzyme 2), the receptor of the virus, is increased by SS (Song et al.
310 2020).

311 These observations support a dual impact of EDCs on IL-17 production and inflammatory
312 state; this impact could be indirect due to the effect of these chemicals on obesity or
313 through a direct stimulation of several signaling pathways, such as AhR or PPAR γ , leading to
314 an overproduction of systemic IL-17; the shear stress pathway represents an additional link
315 between AhR activation and the EDC/disease connection. The implication of shear stress
316 also suggests a possible contribution of increased expression of ACE2, the receptor of the
317 SARS-CoV-2. While the role of these pathways at the nexus between exposure to EDCs and
318 COVID-19 severity appears to be relevant, their actual contribution remains to be
319 demonstrated and their putative role as therapeutic targets remains to be further
320 substantiated.

321 Our integrative systems biology study also indicates a strong statistical association between
322 the AGE/RAGE signaling pathway, chronic diseases and EDC effects. This is likely due to the
323 well-known links between this pathway and type 2 diabetes(Ravichandran et al. 2019).
324 Indeed, hyperglycemia leads to increased amounts of glycation products and their
325 metabolites which results in the activation of the RAGE receptors. The latter are highly
326 expressed in endothelial cells, and their activation leads to increased oxidative stress and
327 inflammation and ultimately to endothelial damage, thrombotic disorders and vascular
328 diseases (Egaña-Gorroño et al. 2020). Other endogenous ligands can also activate RAGE,
329 among them HMGB1 (high-mobility group box 1), an extra-cellular protein also linked to a
330 variety of inflammatory responses(Andersson et al. 2020). Interestingly, the AGE/RAGE
331 signaling pathway is highly expressed in the lung vasculature and has been implicated in
332 several pulmonary diseases(Oczypok et al. 2017). All these observations support the
333 implication of the AGE/RAGE signaling pathway in vascular, thrombotic and lung diseases
334 which are the hallmarks of COVID-19 severity. Interestingly, there are also complex
335 connections between HMGB1 and ACE2 which is the receptor for SARS-Cov2 and other
336 coronaviruses(Luft 2016). These results are in accordance with recent proposals in published
337 commentaries of environmental chemical impacts on COVID-19 progress(Andersson et al.
338 2020; Rojas et al. 2020).

339 The three-way approach did not attempt to identify direct immunotoxic effects due to
340 environmental chemicals otherwise considered to be EDCs. However, some of the EDCs
341 selected, i.e., PCB-153, PFOA and PFOS, are known to have immunotoxic properties
342 (Heilmann et al.), and the same is true for some common air pollutants (Tsatsakis et al.
343 2020). Accordingly, the impact of environmental chemicals on COVID-19 severity demands
344 attention.

345

346 **Conclusions**

347 The results of this computational study appear as a promising initial step toward
348 systematically linking a major group of environmental chemicals to the severity of COVID-19,
349 although the findings need to be further supported by high-throughput screening tests,
350 clinical and experimental data. Nevertheless, these observations bridge environmental
351 stressors and infectious diseases and support an integrated exposome approach. Preliminary

352 focus on the AGE/RAGE and IL-17 pathways illustrates the potential connection between
353 exposure to EDCs and diseases predisposing to COVID-19 severity.

354

355 **Acknowledgments**

356 The authors would like to acknowledge OBERON (<https://oberon-4eu.com/>), a project
357 funded by the European Union's Horizon 2020 research and innovation program under grant
358 agreement no. 825712. This work was also supported by the University of Paris and INSERM.

359 PG is supported by the National Institute of Environmental Health Sciences, NIH

360 (P42ES027706)

361

362 **References**

- 363 Andersson U, Ottestad W, Tracey KJ. 2020. Extracellular HMGB1: a therapeutic target in
364 severe pulmonary inflammation including COVID-19? *Mol Med Camb Mass* 26:42;
365 doi:10.1186/s10020-020-00172-4.
- 366 Audouze K, Brunak S, Grandjean P. 2013. A computational approach to chemical etiologies of
367 diabetes. *Sci Rep* 3:2712; doi:10.1038/srep02712.
- 368 Audouze K, Taboureau O, Grandjean P. 2018. A systems biology approach to predictive
369 developmental neurotoxicity of a larvicide used in the prevention of Zika virus transmission.
370 *Toxicol Appl Pharmacol* 354:56–63; doi:10.1016/j.taap.2018.02.014.
- 371 Bashir MF, Ma BJ, Bilal null, Komal B, Bashir MA, Farooq TH, et al. 2020. Correlation
372 between environmental pollution indicators and COVID-19 pandemic: A brief study in
373 Californian context. *Environ Res* 187:109652; doi:10.1016/j.envres.2020.109652.
- 374 Ben-Jonathan N, Hugo ER, Brandebourg TD. 2009. Effects of bisphenol A on adipokine
375 release from human adipose tissue: Implications for the metabolic syndrome. *Mol Cell*
376 *Endocrinol* 304:49–54; doi:10.1016/j.mce.2009.02.022.
- 377 Bopp SK, Kienzler A, Richarz A-N, van der Linden SC, Paini A, Parissis N, et al. 2019.
378 Regulatory assessment and risk management of chemical mixtures: challenges and ways
379 forward. *Crit Rev Toxicol* 49:174–189; doi:10.1080/10408444.2019.1579169.
- 380 Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. 2020. Endocrine and metabolic
381 link to coronavirus infection. *Nat Rev Endocrinol* 16:297–298; doi:10.1038/s41574-020-0353-
382 9.
- 383 Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. 2012. Oral advanced glycation
384 endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant
385 defenses AGE receptor-1 and sirtuin 1. *Proc Natl Acad Sci U S A* 109:15888–15893;
386 doi:10.1073/pnas.1205847109.
- 387 Cipelli R, Harries L, Okuda K, Yoshihara S, Melzer D, Galloway T. 2014. Bisphenol A modulates
388 the metabolic regulator oestrogen-related receptor- α in T-cells. *Reprod Camb Engl* 147:419–
389 426; doi:10.1530/REP-13-0423.
- 390 Conway DE, Sakurai Y, Weiss D, Vega JD, Taylor WR, Jo H, et al. 2009. Expression of CYP1A1
391 and CYP1B1 in human endothelial cells: regulation by fluid shear stress. *Cardiovasc Res*
392 81:669–677; doi:10.1093/cvr/cvn360.
- 393 Couleau N, Falla J, Beillerot A, Battaglia E, D'Innocenzo M, Plançon S, et al. 2015. Effects of

- 394 Endocrine Disruptor Compounds, Alone or in Combination, on Human Macrophage-Like
395 THP-1 Cell Response. *PLoS One* 10:e0131428; doi:10.1371/journal.pone.0131428.
- 396 Dalsager L, Christensen N, Husby S, Kyhl H, Nielsen F, Høst A, et al. 2016. Association
397 between prenatal exposure to perfluorinated compounds and symptoms of infections at age
398 1-4 years among 359 children in the Odense Child Cohort. *Environ Int* 96:58–64;
399 doi:10.1016/j.envint.2016.08.026.
- 400 Drucker DJ. 2020. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with
401 Therapeutic Implications. *Endocr Rev* 41; doi:10.1210/endo/bnaa011.
- 402 Egaña-Gorroño L, López-Díez R, Yepuri G, Ramirez LS, Reverdatto S, Gugger PF, et al. 2020.
403 Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic
404 Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and
405 Animal Models. *Front Cardiovasc Med* 7:37; doi:10.3389/fcvm.2020.00037.
- 406 Egusquiza RJ, Blumberg B. 2020. Environmental Obesogens and Their Impact on
407 Susceptibility to Obesity: New Mechanisms and Chemicals. *Endocrinology* 161;
408 doi:10.1210/endo/bqaa024.
- 409 Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. 2018. The
410 Reactome Pathway Knowledgebase. *Nucleic Acids Res* 46:D649–D655;
411 doi:10.1093/nar/gkx1132.
- 412 Fattorini D, Regoli F. 2020. Role of the chronic air pollution levels in the Covid-19 outbreak
413 risk in Italy. *Environ Pollut Barking Essex* 1987 264:114732;
414 doi:10.1016/j.envpol.2020.114732.
- 415 Goldberg RB. 2009. Cytokine and cytokine-like inflammation markers, endothelial
416 dysfunction, and imbalanced coagulation in development of diabetes and its complications. *J*
417 *Clin Endocrinol Metab* 94:3171–3182; doi:10.1210/jc.2008-2534.
- 418 Grandjean P, Andersen EW, Budtz-Jørgensen E, Nielsen F, Mølbak K, Weihe P, et al. 2012.
419 Serum vaccine antibody concentrations in children exposed to perfluorinated compounds.
420 *JAMA* 307:391–397; doi:10.1001/jama.2011.2034.
- 421 Granum B, Haug LS, Namork E, Stølevik SB, Thomsen C, Aaberge IS, et al. 2013. Pre-natal
422 exposure to perfluoroalkyl substances may be associated with altered vaccine antibody
423 levels and immune-related health outcomes in early childhood. *J Immunotoxicol* 10:373–
424 379; doi:10.3109/1547691X.2012.755580.
- 425 Gutiérrez-Vázquez C, Quintana FJ. 2018. Regulation of the Immune Response by the Aryl
426 Hydrocarbon Receptor. *Immunity* 48:19–33; doi:10.1016/j.immuni.2017.12.012.
- 427 Han Z, Miwa Y, Obikane H, Mitsumata M, Takahashi-Yanaga F, Morimoto S, et al. 2008. Aryl
428 hydrocarbon receptor mediates laminar fluid shear stress-induced CYP1A1 activation and
429 cell cycle arrest in vascular endothelial cells. *Cardiovasc Res* 77:809–818;
430 doi:10.1093/cvr/cvm095.
- 431 Hartung T, FitzGerald RE, Jennings P, Mirams GR, Peitsch MC, Rostami-Hodjegan A, et al.
432 2017. Systems Toxicology: Real World Applications and Opportunities. *Chem Res Toxicol*
433 30:870–882; doi:10.1021/acs.chemrestox.7b00003.
- 434 Heilmann C, Grandjean P. Immunotoxicity: Impacts and Research Approaches. In: Kishi R,
435 Grandjean P, editors. *Health Impacts of Developmental Exposure to Environmental*
436 *Chemicals*. Singapore: Springer; 2020. pp. 175-90.
- 437 Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. 2019. New approach for
438 understanding genome variations in KEGG. *Nucleic Acids Res* 47:D590–D595;
439 doi:10.1093/nar/gky962.
- 440 Luft FC. 2016. High-mobility group box 1 protein, angiotensins, ACE2, and target organ

441 damage. *J Mol Med Berl Ger* 94:1–3; doi:10.1007/s00109-015-1372-1.

442 Menini S, Iacobini C, de Latouliere L, Manni I, Ionta V, Blasetti Fantauzzi C, et al. 2018. The
443 advanced glycation end-product N^ε-carboxymethyllysine promotes progression of
444 pancreatic cancer: implications for diabetes-associated risk and its prevention. *J Pathol*
445 245:197–208; doi:10.1002/path.5072.

446 Mi H, Muruganujan A, Thomas PD. 2013. PANTHER in 2013: modeling the evolution of gene
447 function, and other gene attributes, in the context of phylogenetic trees. *Nucleic Acids Res*
448 41:D377–386; doi:10.1093/nar/gks1118.

449 Nie W, Lv Y, Yan L, Chen X, Lv H. 2015. Prediction and Characterisation of the System Effects
450 of Aristolochic Acid: A Novel Joint Network Analysis towards Therapeutic and Toxicological
451 Mechanisms. *Sci Rep* 5:17646; doi:10.1038/srep17646.

452 Oczypok EA, Perkins TN, Oury TD. 2017. All the “RAGE” in lung disease: The receptor for
453 advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory
454 responses. *Paediatr Respir Rev* 23:40–49; doi:10.1016/j.prrv.2017.03.012.

455 Pacha O, Sallman MA, Evans SE. 2020. COVID-19: a case for inhibiting IL-17? *Nat Rev*
456 *Immunol* 20:345–346; doi:10.1038/s41577-020-0328-z.

457 Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. 2020. Factors
458 associated with hospital admission and critical illness among 5279 people with coronavirus
459 disease 2019 in New York City: prospective cohort study. *BMJ* 369:m1966;
460 doi:10.1136/bmj.m1966.

461 Piñero J, Queralt-Rosinach N, Bravo À, Deu-Pons J, Bauer-Mehren A, Baron M, et al. 2015.
462 DisGeNET: a discovery platform for the dynamical exploration of human diseases and their
463 genes. *Database J Biol Databases Curation* 2015:bav028; doi:10.1093/database/bav028.

464 Ravichandran G, Lakshmanan DK, Raju K, Elangovan A, Nambirajan G, Devanesan AA, et al.
465 2019. Food advanced glycation end products as potential endocrine disruptors: An emerging
466 threat to contemporary and future generation. *Environ Int* 123:486–500;
467 doi:10.1016/j.envint.2018.12.032.

468 Rojas A, Gonzalez I, Morales MA. 2020. SARS-CoV-2-mediated inflammatory response in
469 lungs: should we look at RAGE? *Inflamm Res Off J Eur Histamine Res Soc Al* 69:641–643;
470 doi:10.1007/s00011-020-01353-x.

471 Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al. 2010. GeneCards
472 Version 3: the human gene integrator. *Database J Biol Databases Curation* 2010:baq020;
473 doi:10.1093/database/baq020.

474 Slenter DN, Kutmon M, Hanspers K, Riutta A, Windsor J, Nunes N, et al. 2018. WikiPathways:
475 a multifaceted pathway database bridging metabolomics to other omics research. *Nucleic*
476 *Acids Res* 46:D661–D667; doi:10.1093/nar/gkx1064.

477 Song J, Hu B, Qu H, Wang L, Huang X, Li M, et al. 2020. Upregulation of angiotensin
478 converting enzyme 2 by shear stress reduced inflammation and proliferation in vascular
479 endothelial cells. *Biochem Biophys Res Commun* 525:812–818;
480 doi:10.1016/j.bbrc.2020.02.151.

481 Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. 2020. Obesity and impaired metabolic
482 health in patients with COVID-19. *Nat Rev Endocrinol*; doi:10.1038/s41574-020-0364-6.

483 Taboureau O, Audouze K. 2017. Human Environmental Disease Network: A computational
484 model to assess toxicology of contaminants. *ALTEX* 34:289–300;
485 doi:10.14573/altex.1607201.

486 Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, et al. 2016. Burden of
487 disease and costs of exposure to endocrine disrupting chemicals in the European Union: an

488 updated analysis. *Andrology* 4:565–572; doi:10.1111/andr.12178.
489 Tsatsakis A, Petrakis D, Nikolouzakis TK, Docea AO, Calina D, Vinceti M, et al. 2020. COVID-
490 19, an opportunity to reevaluate the correlation between long-term effects of
491 anthropogenic pollutants on viral epidemic/pandemic events and prevalence. *Food Chem*
492 *Toxicol Int J Publ Br Ind Biol Res Assoc* 141:111418; doi:10.1016/j.fct.2020.111418.
493 Vandenberg LN, Ågerstrand M, Beronius A, Beausoleil C, Bergman Å, Bero LA, et al. 2016. A
494 proposed framework for the systematic review and integrated assessment (SYRINA) of
495 endocrine disrupting chemicals. *Environ Health Glob Access Sci Source* 15:74;
496 doi:10.1186/s12940-016-0156-6.
497 Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld J-C, et al. 2008. The
498 aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.
499 *Nature* 453:106–109; doi:10.1038/nature06881.
500 Vermeulen R, Schymanski EL, Barabási A-L, Miller GW. 2020. The exposome and health:
501 Where chemistry meets biology. *Science* 367:392–396; doi:10.1126/science.aay3164.
502 Williams AJ, Grulke CM, Edwards J, McEachran AD, Mansouri K, Baker NC, et al. 2017. The
503 CompTox Chemistry Dashboard: a community data resource for environmental chemistry. *J*
504 *Cheminformatics* 9:61; doi:10.1186/s13321-017-0247-6.
505 Wu Q, Achebouche R, Audouze K. 2020. Computational systems biology as an animal-free
506 approach to characterize toxicological effects of persistent organic pollutants. *ALTEX*
507 37:287–299; doi:10.14573/altex.1910161.
508 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. 2020. Clinical course and risk factors for mortality
509 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*
510 *Lond Engl* 395:1054–1062; doi:10.1016/S0140-6736(20)30566-3.
511 Zhu Y, Xie J, Huang F, Cao L. 2020. Association between short-term exposure to air pollution
512 and COVID-19 infection: Evidence from China. *Sci Total Environ* 727:138704;
513 doi:10.1016/j.scitotenv.2020.138704.
514
515
516

517 **Tables**

518

519 **Table 1. List of the 34 major substances known or suspected to be endocrine-disrupting**

520 **chemicals.**

CAS	chemical.name	abbreviation	CAS	chemical.name	abbreviation
35065-27-1	2,2',4,4',5,5'-Hexachlorobiphenyl	PCB-153	446-72-0	genistein	-
1746-01-6	2,3,7,8- Tetrachlorodibenzodioxin	TCDD	3194-55-6	hexabromocyclododecane	HBCD
1912-24-9	atrazine	-	118-74-1	Hexachlorobenzene	HCB
131-56-6	benzophenone-1	-	138261-41-3	imidacloprid	-
117-81-7	Bis (2-ethylhexyl)phthalate	DEHP	625-45-6	methoxyacetic acid	MAA
620-92-8	bisohenol F	BPF	99-76-3	methyl-paraben	MEPA
80-05-7	bisphenol A	BPA	68412-53-3	nonylphenol ethoxylate	NPEO
80-09-1	bisphenol S	BPS	103-90-2	acetaminophen	-
94-26-8	butyl-paraben	BUPA	68631-49-2	PBDE-153	PBDE-153
57-74-9	Chlordane	-	5436-43-1	PBDE-47	PBDE-47
2921-88-2	chlorpyrifos	CPF	14797-73-0	perchlorate	-
				Perfluorooctane sulfonic	
210880-92-5	Clothianidin	-	1763-23-1	acid	PFOS
52315-07-8	cypermethrin	-	335-67-1	Perfluorooctanoic acid	PFOA
486-66-8	daidzein	-	67747-09-5	prochloraz	-
84-74-2	Dibutyl phthalate	DBP	153719-23-4	thiamethoxam	-
72-55-9	Dichlorodiphenyldichloroethylene	DDE	688-73-3	Tributyltin	TBT
50-29-3	dichlorodiphenyltrichloroethane	DDT	3380-34-5	triclosan	-

521

522 **Table 2. List of the 13 diseases.**

Obesity

Impaired respiratory mechanisms respiratory dysfunction

Increased airway resistance respiratory dysfunction

Impaired gas exchange respiratory dysfunction

Low lung volume respiratory dysfunction

Low muscle strength respiratory dysfunction

Cardiovascular disease comorbidities

Diabetes mellitus comorbidities

Kidney disease comorbidities

Hypertension metabolic risk

Prediabetes metabolic risk

Insulin resistance metabolic risk
 Dyslipidemia metabolic risk

523

524 **Table 3. Pathway enrichment for the set of proteins that are linked to both the**
 525 **predisposing diseases and to the EDCs.** The pathways were extracted from the KEGG,
 526 Panther, Reactome and the Wikipathways database.

Data sources	Name of pathways	Proteins*	P-value	FDR**
KEGG	AGE-RAGE signaling pathway in diabetic complications	22	< E-16	< E-16
KEGG	Fluid shear stress and atherosclerosis	20	2.22E-16	1.81E-14
KEGG	TNF signaling pathway	18	8.8E-16	5.79E-14
KEGG	Insulin resistance	17	1.04E-14	5.67E-13
KEGG	Endocrine resistance	15	7.81E-13	2.40E-11
KEGG	MAPK signaling pathway	23	8.84E-13	2.40E-11
KEGG	HIF-1 signaling pathway	15	1.06E-12	2.66E-11
KEGG	Non-alcoholic fatty liver disease (NAFLD)	17	2.83E-12	5.77E-11
KEGG	FoxO signaling pathway	16	5.17E-12	9.36E-11
KEGG	IL-17 signaling pathway	14	6.11E-12	1.05E-10
KEGG	EGFR tyrosine kinase inhibitor resistance	13	1.14E-11	1.85E-10
KEGG	PI3K-Akt signaling pathway	23	3.88E-11	5.51E-10
KEGG	Prolactin signaling pathway	12	4.50E-11	6.12E-10
KEGG	Ras signaling pathway	19	4.91E-11	6.40E-10
KEGG	Thyroid hormone signaling pathway	14	1.32E-10	1.39E-09
KEGG	Toll-like receptor signaling pathway	13	4.08E-10	3.91E-09
KEGG	Insulin signaling pathway	14	1.25E-09	1.07E-08
KEGG	Human T-cell leukemia virus 1 infection	18	1.93E-09	1.57E-08
KEGG	Chronic myeloid leukemia	11	2.02E-09	1.58E-08
KEGG	B cell receptor signaling pathway	10	1.50E-08	1.09E-07
KEGG	T cell receptor signaling pathway	11	4.34E-08	3.01E-07
KEGG	C-type lectin receptor signaling pathway	11	5.90E-08	4.01E-07
Panther	Interleukin signaling pathway	12	1.94E-07	1.10E-05
Panther	Insulin/IGF pathway-protein kinase B signaling cascade	7	1.51E-05	3.42E-04
Panther	Ras Pathway	9	3.61E-05	6.80E-04
Panther	T cell activation	9	6.34E-05	8.95E-04
Panther	PI3 kinase pathway	7	1.12E-04	0.0012
Panther	Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade	5	5.81E-04	0.0050
Panther	Inflammation mediated by chemokine and cytokine signaling pathway	13	8.29E-04	0.0062
Panther	B cell activation	6	0.0026	0.0154
Panther	FGF signaling pathway	8	0.0034	0.0183
Panther	EGF receptor signaling pathway	8	0.0063	0.0324
Panther	Interferon-gamma signaling pathway	2	0.1423	0.5544

Panther	JAK/STAT signaling pathway	1	0.3137	0.9401
Panther	Toll receptor signaling pathway	2	0.3521	0.9947
Reactome	Signaling by Interleukins	31	< E-16	< E-16
Reactome	Interleukin-4 and Interleukin-13 signaling	21	< E-16	< E-16
Reactome	Cytokine Signaling in Immune system	33	5.55E-16	3.20E-13
Reactome	Interleukin-10 signaling	10	1.05E-11	2.85E-09
Reactome	Negative regulation of the PI3K/AKT network	13	1.16E-11	2.85E-09
Reactome	PIP3 activates AKT signaling	18	1.83E-11	3.51E-09
Reactome	PI3K/AKT Signaling in Cancer	12	6.79E-11	1.17E-08
Reactome	Cytochrome P450 - arranged by substrate type	10	3.70E-10	5.81E-08
Reactome	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	11	1.43E-09	2.07E-07
Reactome	Signaling by Receptor Tyrosine Kinases	19	2.43E-08	2.70E-06
Reactome	Insulin receptor signalling cascade	8	2.79E-08	2.84E-06
Reactome	Signaling by Insulin receptor	8	5.25E-07	3.27E-05
Reactome	MAPK family signaling cascades	13	2.57E-06	1.14E-04
Reactome	Constitutive Signaling by Aberrant PI3K in Cancer	7	3.66E-06	1.58E-04
Reactome	Immune System	37	7.14E-06	2.94E-04
Wiki-pathway	Netrin-UNC5B signaling Pathway	15	2.22E-16	1.18E-13
Wiki-pathway	Nonalcoholic fatty liver disease	20	3.06E-14	2.71E-12
Wiki-pathway	Aryl Hydrocarbon Receptor Netpath	12	1.32E-12	6.36E-11
Wiki-pathway	AGE/RAGE pathway	13	3.93E-12	1.61E-10
Wiki-pathway	Insulin Signaling	18	5.35E-12	2.03E-10
Wiki-pathway	RAC1/PAK1/p38/MMP2 Pathway	13	7.18E-12	2.38E-10
Wiki-pathway	Relationship between inflammation, COX-2 and EGFR	9	2.42E-11	7.32E-10
Wiki-pathway	IL-3 Signaling Pathway	11	4.31E-11	1.09E-09
Wiki-pathway	Ras Signaling	18	5.70E-11	1.38E-09
Wiki-pathway	IL-5 Signaling Pathway	10	1.09E-10	2.52E-09
Wiki-pathway	PI3K-Akt Signaling Pathway	23	2.10E-10	4.13E-09
Wiki-pathway	Aryl Hydrocarbon Receptor Pathway	10	7.67E-10	1.13E-08
Wiki-pathway	IL-18 signaling pathway	20	1.09E-09	1.49E-08
Wiki-pathway	Cells and Molecules involved in local acute inflammatory response	7	1.48E-09	1.91E-08
Wiki-pathway	Toll-like Receptor Signaling Pathway	13	1.52E-09	1.93E-08

527 *number of proteins from the studied set that is involved in a pathway

528 ** false discovery rate

529

530

531 **Figure captions**

532


533 **Figure 1. Overview of the integrative systems toxicology approach.** **A:** Human proteins
534 known to be dysregulated by endocrine-disrupting chemicals (EDCs) were extracted from
535 the CompTox database; human proteins linked to obesity or to comorbidities or metabolic
536 dysfunction known to be associated with obesity were compiled using DisGeNET and
537 GeneCards. These compiled data were used to develop a tripartite network. **B:** A set of
538 proteins was identified that was common to both association studies (proteins targeted by
539 the EDCs and also involved in comorbidities). **C:** Biological enrichment was performed for
540 pathways for each of the four databases, by over-representation analysis (ORA) to identify
541 potential mechanisms of action related to these proteins, where the biological pathways
542 were ranked by their statistical significance. **D:** The most relevant of the potential pathways
543 were compared to known COVID-19 dysregulated pathways from the literature and the AOP-
544 Wiki database.

545



546 **Figure 2. Tripartite network representation of endocrine-disrupting chemicals-proteins-**
547 **diseases relationships.** First, a bipartite network of the 208 human proteins known to be
548 dysregulated by the 30 endocrine-disrupting chemicals (EDCs) was created as extracted from
549 the CompTox database. Each yellow diamond node represents an EDC, and edges are the
550 interactions between EDCs and proteins. Then, a second bipartite network was generated
551 for the 4184 human proteins known to be linked to the 13 predisposing diseases, as
552 extracted from the DisGeNET (3262 links) and GeneCards (2079 links) databases. Each red
553 square node represents a disease, and edges are the interactions between diseases and
554 proteins. A total of 1156 proteins were overlapping. All proteins were grouped using the
555 Panther classification system (version 15) and are represented by circles (colors are
556 according to their Panther family classes).

557


558







CompTox, DisGeNET, GeneCards




KEGG, Reactome, Wiki pathways, Panther




























Literature, AOP-Wiki



medRxiv preprint doi: <https://doi.org/10.1101/2020.07.10.20150714>; this version posted July 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).



- | | |
|---|---|
|  cell junction protein |  gene-specific transcriptional regulator |
|  structural protein |  protein modifying enzyme |
|  storage protein |  protein-binding activity modulator |
|  scaffold/adaptor protein |  intercellular signal molecule |
|  translational protein |  cytoskeletal protein |
|  chaperone |  extracellular matrix protein |
|  calcium-binding protein |  defense/immunity protein |
|  transporter |  transfer/carrier protein |
|  transmembrane signal receptor |  cell adhesion molecule |
|  nucleic acid binding protein |  chromatin/chromatin-binding or regulatory protein |
|  membrane traffic protein |  endocrine disrupting chemicals |
|  metabolite interconversion enzyme |  diseases |
|  uncategorized protein class | |